Genentech, a member of Swiss drug maker Roche Group (RHHBY) said Wednesday that the U.S. Food and Drug Administration or FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizumab) as a first-line monotherapy for certain people with advanced non-small cell lung cancer.
from RTT - Biotech https://ift.tt/2V61DjU
via IFTTT
No comments:
Post a Comment